Effects of Combined Topical and Systemic Steroid Administrations on Better Early Postoperative Pain Management in Total Knee Arthroplasty
Total Knee Replacement
About this trial
This is an interventional treatment trial for Total Knee Replacement
Eligibility Criteria
Inclusion Criteria:
- ASA I-III
- Age 18-80 years old (For patients recruited from the Duchess of Kent Children's Hospital at Sandy Bay, they will also be aged from 18 to 80 years old)
- Scheduled for elective primary unilateral total knee replacement
- Chinese patients
- Able to speak and understand Cantonese
- Able to provide informed oral and written consent
Exclusion Criteria:
- Revision total knee replacement
- Single stage bilateral total knee replacement
- Known allergy to opioids, local anaesthetic drugs, paracetamol, non-steroidal anti-inflammatory drugs (NSAIDS) including COX-2 inhibitors
- History of chronic pain other than chronic knee pain
- History of insulin dependent diabetic mellitus, but not diabetic mellitus on oral hyperglycaemic agents
- History of hepatitis B or C carrier
- History of peptic ulcer
- Hx of tuberculosis
- History of immunosuppression
- Daily use of glucocorticoids
- Daily use of strong opioids (morphine, fentanyl, hydromorphone, ketobemidone, methadone, nicomorphine, oxycodone, or meperidine)
- History of severe heart disease (NYHA 2)
- Alcohol or drug abuse
- Impaired renal function, defined as preoperative serum creatinine level over 120 micromol/L
- Pre-existing neurological or muscular disorders
- Psychiatric illness or neurologic or psychiatric diseases potentially influencing pain perception
- Impaired or retarded mental state
- Difficulties in using patient controlled analgesia (PCA)
- Pregnancy
- Local infection
- On immunosuppresants
- Patient refusal
Sites / Locations
- Department of Orthopaedics and Traumatology, The University of Hong KongRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Experimental
Experimental
Placebo Comparator
Group dexamethasone
Group triamcinolone
Group dexamethasone with triamcinolone
Placebo group
A syringe having 4ml of 4mg/ml of dexamethasone is used for intravenous injection
1ml of 40mg triamcinolone is mixed in the syringes containing solution for intrarticualar local infiltration. The solution is injected intraarticularly.
A syringe having 4ml of 4mg/ml of dexamethasone is used for intravenous injection. 1ml of 40mg triamcinolone is mixed in the syringes containing solution for intrarticualar local infiltration. The solution is injected intraarticularly.
A syringe having 4ml of saline is used for intravenous injection. 1ml of saline is mixed in the syringes containing solution for intrarticualar local infiltration. The solution is injected intraarticularly.